Procept (PRCT) Q2 Revenue Jumps 48%
Procept BioRobotics (NASDAQ:PRCT), a medical technology company specializing in robotic surgical systems for benign prostatic hyperplasia (BPH) treatment, posted second-quarter 2025 results on August 6, 2025. The company reported GAAP revenue of $79.2 million, surpassing analyst estimates. The quarter highlighted continued growth in both its U.S. and international segments, as well as notable efficiency gains. Overall, the results pointed to steady momentum, with increasing adoption of its Aquablation therapy platform and ongoing investment in growth.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report.
Procept BioRobotics develops, manufactures, and markets robotic surgical systems for urology, with its core product being the Aquablation therapy platform. Aquablation is a robotic treatment designed to address benign prostatic hyperplasia (BPH), a condition that affects millions of men globally and causes lower urinary tract symptoms due to an enlarged prostate. The company's primary customers are hospitals and physicians specializing in urologic care.
Source Fool.com
